Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin in Advanced Pancreatic Cancer with HRD
NCT06095141Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cisplatin in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Started Dec 2023; status: recruiting.
02
Drugs
cisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06095141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095141.